Argenica Therapeutics (ASX:AGN) Interest Received: A$0.40 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:AGN Argenica Therapeutics Ltd ASX:AGN
26 GF Score
Price A$0.15
! 1 Warning Sign
View Full Analysis

What is Argenica Therapeutics Interest Received?

Argenica Therapeutics ASX:AGN 26 Interest Received is A$0.40 Mil as of Dec. 2025. GuruFocus rates ASX:AGN with a GF Score™ of 26/100. The stock has 1 warning sign investors should review.

Argenica Therapeutics's Interest Received for the six months ended in Dec. 2025 was A$0.14 Mil.

Argenica Therapeutics's Interest Received for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.40 Mil.

Argenica Therapeutics Interest Received Related Terms

Argenica Therapeutics Interest Received Historical Data

* Premium members only.

The historical data trend for Argenica Therapeutics's Interest Received can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Argenica Therapeutics Interest Received Chart

Argenica Therapeutics Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Interest Received
0.00 0.00 0.06 0.09 0.55

Argenica Therapeutics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Interest Received Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.05 0.04 0.29 0.26 0.14
ASX:AGN
26GF Score
Argenica Therapeutics Ltd ASX:AGN
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Argenica Therapeutics Interest Received Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Interest Received represents interest received by the company in the direct cash flow method.

Interest Received for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.40 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Received →
What does a Interest Received of A$0.40 Mil mean?
Argenica Therapeutics (ASX:AGN) has a Interest Received of A$0.40 Mil as of Dec. 2025. Interest Received represents interest received by the company in direct cash flow method. View historical data for Argenica Therapeutics and its competitors.
Is Argenica Therapeutics' Interest Received too high?
Argenica Therapeutics' current Interest Received is A$0.40 Mil. Overall, Argenica Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Argenica Therapeutics' Interest Received compare to VRTX and REGN?
Argenica Therapeutics' Interest Received of A$0.40 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Received for a Biotechnology company?
A good Interest Received depends on the Biotechnology industry context. However, Interest Received should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Received mean?
A high Interest Received can signal that a stock is expensive relative to its fundamentals. Interest Received represents interest received by the company in direct cash flow method. View historical data for Argenica Therapeutics and its competitors. Argenica Therapeutics's current Interest Received is A$0.40 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Argenica Therapeutics stock overvalued right now?
Argenica Therapeutics (ASX:AGN) has a current Interest Received of A$0.40 Mil. The current Interest Received is A$0.40 Mil. Argenica Therapeutics' overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Received calculated?
Interest Received is calculated from a company's financial statements. For Argenica Therapeutics (ASX:AGN), the current Interest Received is A$0.40 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Argenica Therapeutics Business Description

Address 117 Broadway, Unit 4, Nedlands, WA, AUS, 6009
Argenica Therapeutics Ltd is engaged in the research and development of novel drug candidates. Its ARG007 drug improves outcomes in pre-clinical stroke models and its non-clinical studies to other indications and regulatory consultants.
26GF Score

Get the complete analysis for ASX:AGN

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.15
Price